- Home
- / Moderna
Moderna
Program Expenses (Cancer Vaccines)
$3 M
Q1, 2022
Revenue
$18.5 B
FY, 2021
Market Capitalization
$77.2 B
2023-01-19
Moderna Summary
Company summary
- Overview
- Moderna is a biotechnology company that develops therapeutics and vaccines. It provides medicine for treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. The company caters to the healthcare sector.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Cambridge, MA, US | view all locations
- Website
- http://www.modernatx.com
- Cybersecurity rating
- ESG rating
Key people
Noubar Afeyan, Co-founder and Chairman
Stephane Bancel, Chief Executive Officer, Board Member
Juan Andres, Chief Technical Operations and Quality Officer
Operating MetricsView all
Program Expenses (Systemic Intracellular Therapeutics)
$4M
20.0%
Q1, 2022
Program Expenses (Cancer Vaccines)
$3M
82.4%
Q1, 2022
Patent Applications
430
28.3%
FY, 2021
LocationsView all
2 locations detected
Cambridge, MA HQ
United States
200 Technology Square
Norwood, MA
United States
100 Upland Rd
Moderna Financials
Summary financials
- Revenue (Q3, 2022)
- $3.4B
- Gross profit (Q3, 2022)
- $2.3B
- Net income (Q3, 2022)
- $1.0B
- Cash (Q3, 2022)
- $3.0B
- EBIT (Q3, 2022)
- $1.2B
- Enterprise value
- $75.3B
